rs2727271 — FADS2

Intronic variant in FADS2 (delta-6 desaturase) associated with reduced enzyme activity and impaired conversion of plant-based omega-3 (ALA) and omega-6 (LA) precursors into long-chain PUFAs, with the T allele linked to lower circulating EPA and arachidonic acid

See your personal result for FADS2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FADS2 rs2727271 — Your Delta-6 Desaturase Throttle

FADS211 FADS2
Fatty acid desaturase 2, encoding the delta-6 desaturase (D6D) enzyme — the first and rate-limiting step in converting the plant-based omega-3 alpha-linolenic acid (ALA) into EPA and ultimately DHA is one of the most consequential enzymes in human lipid metabolism. It processes both the omega-3 pathway (ALA → stearidonic acid → EPA) and the omega-6 pathway (linoleic acid → gamma-linolenic acid → DGLA → arachidonic acid). Without adequate FADS2 activity, the plant-based omega-3 fats in flaxseed, walnuts, and chia seeds cannot be converted into the long-chain forms that the brain, cardiovascular system, and immune cells actually use.

rs2727271 is an intronic variant within FADS2 on chromosome 11q12-13 that tags a haplotype block associated with altered FADS2 expression. The T allele appears in about 14% of Europeans but in 41% of East Asians, pointing to population-specific evolutionary pressures on fatty acid conversion capacity — likely tied to differences in dietary omega-3 sources across ancestral populations.

The Mechanism

rs2727271 sits deep within an intron of FADS2 (position c.142-1892 relative to the coding sequence), with no direct protein change. Its functional effect is presumed to be cis-regulatory — altering FADS2 mRNA transcription efficiency22 cis-regulatory — altering FADS2 mRNA transcription efficiency
Analogous to the promoter-methylation mechanism of rs174537 in FADS1, where intronic/regulatory variants in the same FADS cluster modulate expression via allele-specific DNA methylation at enhancer sites between FADS1 and FADS2. The T allele is associated with reduced enzyme activity, which produces a predictable biochemical cascade: ALA and linoleic acid accumulate because the first desaturation step is slowed, while downstream long-chain products (EPA, arachidonic acid) are produced at lower rates.

A genome-wide association study identified rs2727271-A (the major allele) as associated with decreased circulating cis/trans-18:2 fatty acid levels (p=7×10⁻⁹), consistent with A-allele carriers more efficiently converting 18:2 precursors through the desaturation pathway. By contrast, T-allele carriers accumulate more precursor fatty acids — a biochemical signature of reduced D6D throughput.

The Evidence

The strongest evidence for the FADS2 locus comes from large genome-wide association studies of circulating polyunsaturated fatty acids. A landmark 2009 GWAS in 1,075 InCHIANTI participants33 landmark 2009 GWAS in 1,075 InCHIANTI participants
Tanaka et al., PLoS Genetics — the FADS1/2/3 cluster on chromosome 11 emerged as the dominant genetic determinant of plasma PUFA levels, with rs174537 alone explaining 18.6% of additive variance in arachidonic acid (p=5.95×10⁻⁴⁶) and associating strongly with EPA (p=1.07×10⁻¹⁴) established that natural variation at this locus has an unusually large effect on fatty acid status — larger than most single SNPs in metabolic genetics.

Subsequent studies refined the picture for FADS2 specifically. Zec et al. 2020 in Nutrition Research44 Zec et al. 2020 in Nutrition Research
Cross-sectional study of 286 Serbian adults; FADS2 rs174576 minor allele carriers showed plasma AA β=−1.14 (95% CI: −2.25 to −0.43) and reduced estimated desaturase-5 activity after multivariate adjustment confirmed that FADS2 minor alleles consistently associate with lower arachidonic acid. Schuchardt et al. 201655 Schuchardt et al. 2016
111 MCI patients; FADS2 minor allele carriers at rs3834458, rs1535, rs174575, and rs174576 showed higher precursor PUFA levels and lower AA in erythrocyte membranes demonstrated that the effect on circulating PUFA composition is detectable in red blood cell membranes — the most clinically relevant tissue compartment for omega-3 status assessment.

Isotope tracer work directly quantifying in-vivo ALA conversion found that FADS minor allele homozygotes had lower plasma EPA and lower [13C]EPA enrichment at 24 and 48 hours after ALA tracer dosing66 FADS minor allele homozygotes had lower plasma EPA and lower [13C]EPA enrichment at 24 and 48 hours after ALA tracer dosing
Gillingham et al. 2013, Am J Clin Nutr, n=103; four FADS SNPs studied across all dietary conditions, providing direct mechanistic confirmation that reduced FADS activity translates into measurably less ALA-to-EPA conversion.

The East Asian frequency of the T allele (41%) versus African populations (3%) is striking. This stratification suggests that the T allele may have been neutral or mildly adaptive in populations historically relying on preformed dietary EPA and DHA from fish, while being selected against in populations that depended more on plant-based omega-3 conversion.

Practical Actions

For T-allele carriers, the core problem is that plant-based omega-3 sources (flaxseed, chia, walnuts, hemp) are unreliable. These foods supply ALA, which requires functional FADS2 to produce EPA and DHA. The T allele slows this conversion at the first and rate-limiting step, meaning even high ALA intakes may not translate to adequate EPA and DHA status.

The practical solution is to bypass the impaired conversion step by providing preformed EPA and DHA directly — from fatty fish, concentrated fish oil, or algae-based EPA/DHA supplements. AT heterozygotes benefit from 1–2 g EPA+DHA daily; TT homozygotes require 2–4 g daily to compensate for substantially reduced D6D throughput.

Omega-3 index testing (erythrocyte EPA+DHA as a percentage of total fatty acids) provides the most direct readout of whether supplementation is working. A value below 4% indicates clinically significant deficiency requiring dose adjustment.

Interactions

rs2727271 is in linkage disequilibrium with other FADS2 cluster variants, including rs3834458, rs174575, rs174576, and rs1535. Carrying multiple minor alleles across the FADS cluster (both FADS1 rs174537 T allele and FADS2 rs2727271 T allele) would compound the conversion deficit, since FADS1 (delta-5 desaturase) acts downstream of FADS2 in the same pathway. Combined FADS1+FADS2 minor allele carriers face a double bottleneck in long-chain PUFA synthesis.

FADS2 activity is also substrate-competitive: when dietary saturated fat (palmitic acid, 16:0) is high, FADS2 preferentially processes the saturated substrate rather than ALA or linoleic acid, further reducing long-chain PUFA synthesis in T-allele carriers who have less enzyme capacity to begin with.

Nutrient Interactions

omega-3 fatty acids (ALA) impaired_conversion
eicosapentaenoic acid (EPA) increased_need
docosahexaenoic acid (DHA) increased_need
linoleic acid (LA) altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal FADS2 Activity Normal

Full delta-6 desaturase activity — efficient conversion of plant-based omega-3

You carry two copies of the A allele at rs2727271, the common variant associated with normal FADS2 (delta-6 desaturase) expression and activity. Your body efficiently runs the first step of converting plant-based omega-3 alpha-linolenic acid (ALA from flaxseed, chia, walnuts) toward EPA, and linoleic acid (from vegetable oils) toward arachidonic acid. About 73% of people of European descent share this genotype. Although you convert ALA to EPA more efficiently than T-allele carriers, the baseline conversion rate in humans is still modest (typically under 10% of ALA reaching EPA, and under 1% reaching DHA). Adequate dietary intake of preformed EPA and DHA from marine sources remains important regardless of genotype — your FADS2 genotype simply means you extract somewhat more value from plant-based omega-3 sources than people with the T allele.

AT Intermediate FADS2 Activity Intermediate

One T allele — partial reduction in delta-6 desaturase activity and ALA conversion

Heterozygous carriers of the FADS2 T allele are expected to show intermediate desaturase activity — producing less FADS2 enzyme than AA homozygotes but retaining partial function. Studies of closely related FADS2 cluster variants (rs3834458, rs174575, rs1535) consistently show that minor-allele heterozygotes have precursor fatty acid levels intermediate between the two homozygous groups, confirming a codominant inheritance pattern for desaturase activity. In the omega-6 pathway, AT carriers may also show slightly reduced conversion of linoleic acid to gamma-linolenic acid and downstream to arachidonic acid. This can be relevant in inflammatory conditions where AA-derived eicosanoids play a role.

TT Reduced FADS2 Activity Poor Converter

Two T alleles — substantially reduced delta-6 desaturase activity and impaired long-chain PUFA synthesis

The TT genotype at rs2727271 likely produces the lowest FADS2 expression state at this locus. Studies of the broader FADS2 haplotype block consistently show that minor allele homozygotes have substantially impaired conversion of both omega-3 and omega-6 precursors: less ALA becomes EPA, and less linoleic acid becomes arachidonic acid. The dual-pathway impairment is important clinically. In the omega-3 pathway, reduced EPA and DHA synthesis affects cardiovascular, neurological, and inflammatory outcomes. In the omega-6 pathway, reduced arachidonic acid production means lower baseline pro-inflammatory eicosanoid potential — a double-edged effect where lower AA may confer some protection from inflammation-driven disease, but the companion EPA deficit requires active correction through diet or supplementation. Isotope tracer studies confirm the mechanism is not compensated by higher ALA intake alone: even when minor-allele subjects consumed high ALA diets, their plasma [13C]EPA enrichment was significantly lower than major-allele subjects at 24 and 48 hours post-dose. The conversion ceiling is genetically set. Direct supplementation with preformed EPA and DHA efficiently corrects the deficit — absorption and incorporation of supplemental EPA is not impaired, only the endogenous conversion.